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Dr Blair A. Keagy (Chapel Hill, NC). We have been privi-
leged to hear a presentation by some of the leaders in the field of
endovascular aneurysm repair. Their experience is noteworthy and
the quality of their work speaks for itself. I have several comments
regarding the statistics used in this manuscript. The authors have
convincingly shown that the presence or absence of an endoleak at
30 days is predictive of a subsequent adverse event. I performed a
2 analysis on their data correlating the 30-day leak with a 1-year
adverse event rate and this again supports the validity of their
thesis.
However, if this parameter is to be used as a screening test, the
predictive value is important, which is defined as the probability
that the test is correct when applied to the individual patient in
the population of interest. When making such calculation, based
theorem assumes importance. Based theorem says that the predic-
tive value of a diagnostic study is dependent on the prevalence in
the disease in the population of interest. With my calculations, I
made the assumption of a 15% endoleak rate, which was based on
the essay author’s observations. The formula predictive value is
true positives divided by true positives plus false positives. This
would result in a predictive value for this screening test of 37%.
This may not be acceptable for making decisions regarding further
follow-up.
I would also question the definition of adverse events. These
are listed as rupture open conversion, any secondary intervention
linked thrombosis migration, renal morbidity, valve expansion due
to pseudoaneurysm. In the abstract, it is stated that the adverse
event rate was retrospectively calculated. This could be construed
as a form of data mining and would mandate a further prospective
study.
The investigators used a Kaplan-Meier or life-table analysis in
their study. In the 5 years, the number of actual patients was less
than 20% of the original cohort. Therefore, it would have been
helpful if standard error bars had been included on the graphs.
The investigators mentioned the use of ultrasound in their
paper as a means of long-term follow-up, but gave no details of
when it was employed in this report. Also, they do not comment on
whether or not they used an implanted pressure sensor in any ofI agree with the authors’ concern as to the risk of repeated CT
scans, including renal failure cost and a potential cardiogenic risk.
It is stated that many of the endoleaks in this study were type II and
that many of these types of endoleaks may not be benign. I would
appreciate more information on how type II endoleaks should be
treated. In summary, I commend the authors on their presentation
and the quality of their work. To summarize my questions, they
are:
1. Are the authors satisfied with the presence of a 30-day or 1-year
endoleak rate as a sufficient screening test to change the way in
which vascular aneurysm patients are followed?
2. What other modalities such as ultrasound or pressure sensor
implantation would be helpful in following patients after endo-
vascular aneurysm repair?
3. How should type II endoleaks be followed?
4. Is the retrospective definition of adverse events acceptable?
5. How are patients with multiple adverse events handled in this
analysis?
DrW. Charles Sternbergh III. I appreciate those comments
and I will try to answer all those questions. Please prompt me if I
have missed any. Is it reasonable to change our surveillance algo-
rithm based on these data? That is really the crux of the question.
Those patients with no endoleak and a shrinking aneurysm sac at 1
year had a subsequent 5-year risk of aneurysm-related morbidity of
approximately 5%. While I don’t qualify as a statistician, it appears
to me that this adverse event rate is acceptably low. Those data
were really our basis for suggesting that we can change our
surveillance strategy.
One of the most important take home points is that those
patients with no endoleak throughout the entire study still had
about a 10% risk of some aneurysm-related morbidity. We have
always been keyed on looking at endoleak and the problems with
endoleak, but clearly that does not define all of the problems that
we see.
Regarding the second question concerning use of ultrasound
or pressure sensors, it was up to the investigator in terms of patients
with advanced renal insufficiency, whether or not they used ultra-
sound. It certainly wasn’t used routinely through the study, nor
were pressure sensors used.
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investigator. Most of us tended to treat endoleaks only if the
aneurysms were increasing in size. Early in the experience, I
believe that majority of type II endoleaks treated were done by
in whom more relaxed surveillance regimens may be appropriate.
However, there was a 10.5% risk of ARM at 5 years in patients whocoil embolization. Translumbar glue embolization really wasn’t
being used with great frequency during this time, but perhaps
in the latter part of the trial, was used with some increased
frequency.INVITED COMMENTARYCaron Rockman, MD, New York, NY
The issue of the absolute necessity of life-long surveillance in
patients who have undergone endovascular abdominal aortic an-
eurysm repair (EVAR) is certainly an important and timely topic
from a number of perspectives. Clearly, there are appropriate
medical concerns regarding the repetitive use of iodinated contrast
materials and their possible cumulative deleterious effects on renal
function as well as apprehension regarding potential carcinogenic
consequences of recurring radiation exposure. In addition, the
issue of the societal cost of these studies cannot be completely
overlooked from a global health care standpoint.
To address these concerns, a variety of alternative forms of
surveillance in EVAR patients have been proposed, including
noncontrast computed tomography (CT) studies, traditional and
contrast-enhanced duplex ultrasound, gadolinium-enhanced mag-
netic resonance imaging, implantable wireless sac pressure sensors,
and intravascular ultrasound. However, currently the precise role
and accuracy of these alternatives remains ill defined.
The current study presents notable information. Patients with
an absence of early endoleak on a 30-day CT scan had a significant
reduction in aneurysm-related morbidity (ARM) at 1 to 5 years. It
should be noted, however, that although the definition of ARM
included obvious events such as aneurysm-related death, rupture,
endograft migration, and open conversion, it also included “sec-
ondary interventions,” which intuitively would be expected to be
more prevalent in patients with known endoleaks. Patients with a
cumulative absence of endoleak at 6 months (79.4% of patients)
and at 1 year (77.6% of patients), however, had an identical 5-year
freedom from any type of ARM. The authors state, therefore, that
routine surveillance for continued absence of endoleak at 6months
and 1 year did not greatly alter the predicted 5-year freedom from
ARM.
They conclude that the absence of an early endoleak therefore
identifies a cohort of patients at substantially reduced risk for ARMhad never experienced an endoleak. In addition, it is correctly
pointed out that not all ARM (for example, graft limb thrombosis)
will necessarily be predicted by an abnormality seen on a routinely
performed imaging study; nor can all ARM be prevented by even
very aggressive surveillance and monitoring programs.
Finally, in the Zenith trials there was a population of patients
in whom a delayed endoleak occurred: A 12% to 15% risk of late
endoleak, most often of type II, was noted even when no leak was
identified on the initial 30-day CT scan. The clinical significance of
these delayed leaks remains unclear. At our institution we have
anecdotally seen a number of patients in whom 3 or 4 years of
initially negative CT follow-up was subsequently followed by the
novel appearance of an endoleak on the next annual CT scan.
Several of these late leaks eventually required secondary interven-
tion and treatment.
The recommendations of the current study, although attrac-
tive, should be interpreted with caution. As the authors correctly
point out, these excellent results were obtained only using one type
of commercially available aortic stent graft system. In addition, and
perhaps even more importantly, these results were obtained in
patients who underwent intervention as part of a strictly controlled
clinical trial. As such, these patients represent a cohort of cases with
ideal anatomic parameters, and the long-term results are likely not
applicable to post-trial EVAR cases, in which preoperative ana-
tomic selection criteria is likely to have been relaxed by the indi-
vidual practitioner.
If the algorithm adopted in the article had been strictly fol-
lowed in this cohort of patients, this would have resulted in 23.4%
of patients having no routinely prescribed follow-up except for a
yearly ultrasound study after their negative result on the 1-year CT
scan. Even this excellent and compelling data and analysis do not
support such a radical change in follow-up protocols at the present
time. Although there undoubtedly exists a cohort of patients who
may not require lifelong intensive surveillance imaging after
EVAR, they remain imprecisely characterized at the present time.
